Pharma in Brief: The 2021 Year in Review

In this article, the Pharma in Brief team has curated and provided updates on the most significant topics we covered in 2021. Introduction In 2021, governments advanced major policy initiatives aimed at the COVID-19 pandemic and broader health priorities. These policy initiatives included reforms to the Patented Medicine Prices Review Board (PMPRB), the Patented Medicines … Read more

Part I – Introduction and Laying the Genus/Species Foundation

“In re Baird illustrates that the disclosure of a genus in the prior art is not necessarily a disclosure of every species that is a member of that genus. Patentees can use this concept to their advantage in applying for solid-form patents.” Pharmaceutical products are typically dosed as solids, liquids (eg, solutions) or gases. In … Read more

Federal Court rejects motion for summary judgment in Canadian patent infringement case following voluntary dismissal of parallel US litigation

In a recently released decision, the Federal Court (FC) considered what happens when a patent infringement plaintiff agrees to resolve a dispute in a foreign jurisdiction, but continues to press parallel litigation against the same defendant in Canada. In this case, the defendant sought summary judgment based on the terms of a voluntary dismissal between … Read more

I-MAK Defends Integrity of Its Patent Data in Response to Tillis Letter

“At the time of writing in 2018, 11 out of the 12 drugs did not have any generic or biosimilar competition in the United States. Even the drug that did have competition (Remicade) at the time of writing was limited to only one competitor.” I-MAK letter The Initiative for Medicines, Access & Knowledge (I-MAK) has … Read more